info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Central Nervous System Biomarkers Companies

Central Nervous System (CNS) biomarkers are crucial indicators that can be measured objectively and used as a diagnostic tool or to monitor the progression of various neurological disorders. Several companies specialize in the development and application of CNS biomarkers for research, diagnostics, and therapeutic development.

Central Nervous System Biomarkers Market

 


Latest Central Nervous System Biomarkers Companies Updates:


Eisai Co., Ltd. and Biogen Inc. (US): Presented research at a recent conference exploring the use of plasma-based biomarkers in the Phase 3 AHEAD 3-45 study of lecanemab (BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody for Alzheimer's disease. This highlights the ongoing focus on blood-based biomarkers for easier and less invasive testing.


Diadem (US): Published clinical data showing its AlzoSure biomarker test can predict the progression of Alzheimer's disease years before symptoms appear. This breakthrough offers potential for early intervention and personalized treatment strategies.


Roche (Switzerland): Announced FDA approval for its Elecsys® Neuro kit for measuring tau protein in cerebrospinal fluid, aiding in the diagnosis of Alzheimer's disease and other neurodegenerative conditions.


Lumosity (US): Partnered with the University of California, San Francisco (UCSF) to develop and validate novel digital cognitive assessments and biomarkers for early detection of


Alzheimer's disease. This collaboration combines traditional research with digital health approaches.


Quanterix Corporation (US): Showcased its Simoa® technology platform at a medical conference, highlighting its potential for ultrasensitive detection of various CNS biomarkers, including tau and synuclein alpha, for early diagnosis of neurodegenerative diseases.


List of Central Nervous System Biomarkers Key companies in the market:



  • Thermo Fisher Scientific (US)

  • Merck & Co. (US)

  • AbaStarMDx Inc. (US)

  • Abiant, Inc. (US)

  • Avacta Group plc (UK)

  • Diagenic Asa (Norway)

  • Banyan Biomarkers (US)

  • Avid Radiopharmaceuticals Inc. (US)

  • Acumen pharmaceuticals Inc. (US)


Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.